ARCHIVES

NTP Board Approves $4 Million Mouse Variation Concept

This article is from The Cancer Letter archive.

Vol. 11 No. 45 | November 22, 1985

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends Approval of Evista for Breast Cancer Risk Reduction.

July 27, 2007

Group trials need prioritization, review, NCI official says.

July 25, 2003

NCI Viewed As NIH’s ‘Administrative Reserve,” Broder Tells Directors

July 12, 1991

In Brief: Leonidas Platanias named director of Lurie Comprehensive Cancer Center

October 3, 2014

CALGB Chairman Schilsky To Step Down After 15 Years Leading Cooperative Group.

February 1, 2008

Interim Analysis of Phase III Data Preferable For Accelerated Approval, FDA’s Pazdur Says

September 6, 2002